Propellon Therapeutics
Toronto
About Propellon Therapeutics
Propellon Therapeutics is developing and commercializing novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival. Established by FACIT, Propellon’s WDR5 inhibitor platform arises from discoveries, research and innovations originating from OICR.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.0M
- Funding stage: Seed
- Last round: Seed (Mar 2017)
Industries & Categories
Biotechnology, Life Science, Therapeutics
Canonical: https://fsome.com/organization/propellon-therapeutics-82836 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.